Stephenson Harwood LLP has advised bd-capital and the management team of Symprove, a UK-based probiotic manufacturer, on the sale of the company to Metagenics.
Metagenics and its sponsor, Gryphon Investors, also completed a concurrent strategic debt recapitalisation to provide Metagenics with capital to continue investing in organic and M&A growth opportunities.
Symprove’s water-based formulation addresses digestive illnesses and discomfort and is focused on improving the health of users’ gut microbiome. Since bd-capital’s investment in 2020, Symprove has more than tripled in size and helped hundreds of thousands of people live healthier lives. bd-capital is a pan-European investment firm focused on partnering with growing businesses in the healthcare, services and consumer sectors. Metagenics is a California-based global provider of nutritional supplements.
The Stephenson Harwood team was led by Private Equity Partners Chris Manning and Malcolm MacDougall, with assistance from Managing Associates Rajiv Kakkad and Adrian Moss, and Associates Alex Aveyard and Harry House. The Private Equity Team was assisted by specialists from across the firm including Nicholas Stretch and Luc Foley in the Employee Incentives team, Richard Freedman, Katie Woods and Eleanor Bullen-Bell in the Employment team, Kate Worthington and Byul McPhee in the Tax team and Julie Romer and Katherine Emerson in the Finance team.
Partner
London
Partner
London
Managing Associate
London
Managing Associate
London
Associate
London
Associate
London
Partner
London
Partner
London
Partner
London
Partner
London
Associate
London
Associate
London
Associate
London
Managing Associate
London
Associate
London
